Times are changing. A renewed interest from big pharma in the rare disease landscape has awakened due to large-scale patent expirations, competition from generics & biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care reform. This means that the traditional blockbuster model has become less viable while the revenue-generating potential of orphan drugs has shown to be huge with a greater return on investment than non-orphan drugs. According to EvaluatePharma, the orphan drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of prescription drugs by 2020, totalling 176 billion dollars.